Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie collaboration boosts Halozyme stock

This article was originally published in Scrip

Executive Summary

AbbVie is paying oncology-focused biotech Halozyme Therapeutics $23m upfront, and up to $130m in potential milestone payments for each of up to nine collaboration targets, in order to get access to the company's Enhanze drug delivery platform.

You may also be interested in...



Halozyme's 2017 Includes PEGPH20 Milestones, New Partnership

Halozyme CEO Helen Torley spoke with Scrip about execution of the company's strategy – reworked after her arrival in 2014 – to focus on oncology drug development and partnerships using its Enhanze platform.

BMS: Retaining Top Talent Through An Acquisition And A Pandemic

Catherine Owen joined Bristol Myers Squibb in September 2019, tasked with overseeing the integration of Celgene and BMS’s international businesses. She talks to In Vivo about managing the merger of teams from two very distinct companies during a global pandemic. Owen, who is passionate about career growth and mentoring, also highlights the importance of talent development and sponsorship – even in times of uncertainty, when business as usual goes out the window. 

Pharma-Biotech Licensing Trends To Watch For In 2021

More option deals, greater use of alternative remedy clauses and aggressive diligence of assets. Geoffrey Spolyar, special counsel at Cooley, spotlights some of the changes he is seeing in pharma and biotech partnership agreements and explains why these trends matter in 2021.

Topics

Related Companies

UsernamePublicRestriction

Register

SC028900

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel